Pharming Group (NASDAQ:PHAR - Get Free Report) saw an uptick in trading volume on Tuesday . 5,484 shares were traded during trading, an increase of 7% from the previous session's volume of 5,115 shares.The stock last traded at $8.83 and had previously closed at $8.78.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on PHAR. Jefferies Financial Group began coverage on shares of Pharming Group in a report on Monday, December 9th. They set a "buy" rating and a $14.00 price target on the stock. Oppenheimer cut their price target on shares of Pharming Group from $31.00 to $30.00 and set an "outperform" rating on the stock in a report on Monday, October 28th. Finally, HC Wainwright restated a "buy" rating and set a $37.00 price target on shares of Pharming Group in a report on Tuesday, December 17th.
Read Our Latest Stock Report on PHAR
Pharming Group Stock Up 3.2 %
The company has a market capitalization of $621.18 million, a PE ratio of -35.12 and a beta of -0.10. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The stock's 50 day moving average is $9.30 and its 200 day moving average is $8.44.
Institutional Trading of Pharming Group
An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its position in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 47,997 shares of the company's stock after acquiring an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 as of its most recent filing with the Securities and Exchange Commission. 0.03% of the stock is owned by institutional investors and hedge funds.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Articles
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
